Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $5.3500 (2.69%) ($5.1500 - $5.5300) on Tue. Oct. 15, 2019. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.46% (three month average) | RSI | 39 | Latest Price | $5.3500(2.69%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX advances 1% a day on average for past five trading days. | Weekly Trend | TGTX declines -2.6% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(65%) ARKG(58%) IBB(57%) ARKK(56%) IWO(56%) | Factors Impacting TGTX price | TGTX will decline at least -1.73% in a week (0% probabilities). VIXM(-39%) VXX(-37%) TLT(-8%) UUP(-7%) IGOV(-2%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -1.73% (StdDev 3.46%) | Hourly BBV | 0 () | Intraday Trend | 2.7% | | | |
|
Resistance Level | $5.5 | 5 Day Moving Average | $5.22(2.49%) | 10 Day Moving Average | $5.22(2.49%) | 20 Day Moving Average | $5.5(-2.73%) | To recent high | -32.9% | To recent low | 4.9% | Market Cap | $678m | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |